The Structural Genomics Consortium (SGC) is a global public-private partnership dedicated to open science.

Uncovering the human genome and accelerating drug discovery through open science collaboration

Led from Toronto, Canada, the SGC is a pre-competitive public-private partnership in the areas of structural and chemical biology, and drug discovery.  The SGC was founded in 2003 with two main laboratories at the Universities of Toronto and Oxford.  The current SGC laboratories are located at Goethe University Frankfurt, Karolinska Institutet, McGill University, University College London, the University of North Carolina Chapel Hill and the University of Toronto and constitute a network of approximately 250 scientists. SGC scientists collaborate with scientists in each of its partner companies, currently Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Janssen, Merck, Pfizer and Takeda.

The SGC mission is to understand all proteins encoded by the human genome and accelerate the discovery of new medicines 

Over its first 20 years, SGC scientists determined the structures of thousands of human proteins and collaborated closely with industry scientists to invent and disseminate hundreds of chemical probes, which are well-characterized modulators of protein function that can be used to validate or invalidate proteins as drug targets.  These chemical probes have been used by thousands of scientists around the world to make discoveries and to seed new drug discovery programs. 

In the next ten years, the SGC will focus on the aims of Target 2035, a global effort created to develop pharmacological tools to modulate every protein in the human proteome by the year 2035.  

Our Open Science Approach 

Our pioneering open science model for protein science, chemical biology and drug discovery adheres to the principles that all data, reagents and tools generated by SGC scientists (including those developed in collaboration with partners from the private sector and academia) must be made publicly available (deposited into public databases) without any restrictions on their use.  This approach provides investigators, partners, and collaborators with the freedom to operate while also saving significant resources, enhancing the quality of global research, and accelerating early-stage drug discovery for all.

Mission and Vision 

Our Mission
To understand the function(s) of all proteins encoded by the human genome and accelerate the discovery of new medicines.

Our Vision
To mobilize and inspire a global community to work toward our mission.